文献速递糖尿病

新型糖尿病药物心血管与肾脏获益按基线心血管风险的系统评价、Meta分析与Meta回归

Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.
PubMed 文献 · Diabetes Care · 2023-01-01

该系统评价纳入9项GLP-1RA和13项SGLT2i随机试验共154,649例患者,评估不同基线心血管风险下心血管与肾脏获益差异。结果显示相对效应在各风险水平保持一致,但绝对获益随风险升高而增加,尤其SGLT2i对心衰的绝对获益在高风险患者中增至11.6%。

要点

  • GLP-1RA与SGLT2i的相对心血管与肾脏获益在各基线心血管风险水平保持一致。
  • 绝对获益随基线心血管风险升高而增加,尤其SGLT2i对心衰的5年绝对风险降低在高风险患者中达11.6%。
  • 作者认为需要基线风险评估工具来识别绝对治疗获益的差异并改善决策。

核心结论

  • 新型糖尿病药物的相对效应在各基线心血管风险水平保持一致,而绝对获益在高风险患者中增加,尤其关于心衰。
  • 作者认为需要基线风险评估工具来识别绝对治疗获益的差异并改善决策。

研究设计与样本

  • 系统评价、Meta分析与Meta回归,检索PubMed至2022年11月7日。
  • 纳入GLP-1RA与SGLT2i的确证性随机试验,对象为成人患者,需有安全性或有效性终点数据。
  • 共分析9项GLP-1RA试验和13项SGLT2i试验,合计154,649例患者。

主要发现

  • 心血管死亡率汇总HR:GLP-1RA为0.87,SGLT2i为0.86。
  • 主要不良心血管事件汇总HR:GLP-1RA为0.87,SGLT2i为0.88。
  • 心衰汇总HR:GLP-1RA为0.89,SGLT2i为0.70。
  • 肾脏结局汇总HR:GLP-1RA为0.84,SGLT2i为0.65。
  • 卒中疗效仅GLP-1RA显著(HR 0.84),SGLT2i不显著(HR 0.92)。

关键数值与推荐

  • SGLT2i试验中高风险患者的5年绝对风险降低(0.80-4.25%)增至心衰的11.6%(Pslope < 0.001)。
  • GLP-1RA试验中对照臂心血管死亡率与HR的关联不显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 分析受限于缺乏患者水平数据。
  • 分析受限于终点定义的一致性不足。
  • 分析受限于GLP-1RA试验中心血管死亡率的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with diabetes at lower cardiovascular risk, but whether treatment benefits differ by risk levels is not clear. PURPOSE: To investigate whether patients with varying risks differ in cardiovascular and renal benefits from GLP-1RA and SGLT2i with use of meta-analysis and meta-regression. DATA SOURCES: We performed a systematic review using PubMed through 7 November 2022. STUDY SELECTION: We included reports of GLP-1RA and SGLT2i confirmatory randomized trials in adult patients with safety or efficacy end point data. DATA EXTRACTION: Hazard ratio (HR) and event rate data were extracted for mortality, cardiovascular, and renal outcomes. DATA SYNTHESIS: We analyzed 9 GLP-1RA and 13 SGLT2i trials comprising 154,649 patients. Summary HRs were significant for cardiovascular mortality (GLP-1RA 0.87 and SGLT2i 0.86), major adverse cardiovascular events (0.87 and 0.88), heart failure (0.89 and 0.70), and renal (0.84 and 0.65) outcomes. For stroke, efficacy was significant for GLP-1RA (0.84) but not for SGLT2i (0.92). Associations between control arm cardiovascular mortality rates and HRs were nonsignificant. Five-year absolute risk reductions (0.80-4.25%) increased to 11.6% for heart failure in SGLT2i trials in patients with high risk (Pslope < 0.001). For GLP1-RAs, associations were nonsignificant. LIMITATIONS: Analyses were limited by lack of patient-level data, consistency in end point definitions, and variation in cardiovascular mortality rates for GLP-1RA trials. CONCLUSIONS: Relative effects of novel diabetes drugs are preserved across baseline cardiovascular risk, whereas absolute benefits increase at higher risks, particularly regarding heart failure. Our findings suggest a need for baseline risk assessment tools to identify variation in absolute treatment benefits and improve decision-making.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Valadez JM, Tahsin M, Fleischmann KE, et al. Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression. Diabetes Care. 2023. PMID: 37220263. doi:10.2337/dc22-0772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。